Skip to main content

Table 1 Clinical and treatment characteristics of prostate cancer cases

From: Geographic and outcome variation among black men diagnosed with prostate cancer

Characteristic US-born Brooklyn
N = 125
N (%)
African-born Brooklyn
N = 37
N (%)
Caribbean-born Brooklyn
N = 406
N (%)
Caribbean-born Trinidad &Tobago
N = 1,594
N (%)
P-Value
Histology      
Carcinoma, NOS 4 (3.2) 2 (5.4) 5 (1.2) 177 (11.1) <0.0001
Adenocarcinoma 121 (96.8) 35 (94.6) 397 (97.8) 1,406 (88.2)  
Other1 0 (0.0) 0 (0.0) 4 (0.99) 11 (0.7)  
Stage      
I-III 111 (88.8) 32 (86.5) 367 (90.4) 953 (59.8) <0.0001
IV 12 (9.6) 3 (8.1) 27 (6.7) 338 (21.2)  
Unstaged 2 (1.6) 2 (5.4) 12 (3.0) 303(19.0)  
Treatment      
Stage I-III N = 111 N = 32 N = 367 N = 953 <0.0001
No treatment 32 (28.8) 9 (28.1) 54 (14.7) 250 (26.2)  
Surgery only 34 (30.6) 10 (31.2) 128 (34.9) 107 (11.2)  
Radiotherapy only 29 (26.1) 5 (15.6) 83 (22.6) 64 (6.7)  
Hormone therapy only 0 (0.0) 0 (0.0) 13 (3.5) 295 (31.0)  
Combination therapy* 16 (14.4) 8 (25.0) 89 (24.3) 237 (24.9)  
Treatment      
Stage IV N = 12 N = 3 N = 27 N = 338 0.295
No treatment 6 (50.0) 1 (33.3) 9 (33.3) 124 (36.7)  
Surgery only 2 (16.7) 0 (0.0) 1 (3.7) 13 (3.9)  
Radiotherapy only 2 (16.7) 1 (33.3) 2 (7.4) 32 (9.5)  
Hormone therapy only 2 (16.7) 1 (33.3) 9 (33.3) 74 (21.9)  
Combination therapy* 0 (0.0) 0 (0.0) 6 (22.2) 95 (28.1)  
  1. *Combination refers to any combination of surgery, radiation and hormone therapy or at least two different types of therapy. 1Other (histology): Glandular intraepithelial neoplasia, grade III; Small cell carcinoma; Squamous cell carcinoma; Transitional cell carcinoma; Cribriform carcinoma; Acinar cell carcinoma and Sarcoma.